Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 21, 2025 17:55 UTC |
Cavorsi RobertVice President, Strategy
|
GrantClass A Common Stock | 61,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003235 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,463 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:36 UTC |
Driscoll Michael JosephDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003204 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,879 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:53 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantStock Option (Right to Buy) · Derivative | 43,956 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003231 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,956 Underlying: Class A Common Stock · 43,956 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:53 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 42,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003231 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,680 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:45 UTC |
Leibowitz Arthur SDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003217 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,186 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:51 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 167,625 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003226 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,625 Underlying: Class A Common Stock · 167,625 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:51 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantClass A Common Stock | 162,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003226 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 594,195 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:41 UTC |
Giacomin Jon LDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003210 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,198 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:54 UTC |
Bilbo PatrickChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 190,475 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003233 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,475 Underlying: Class A Common Stock · 190,475 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:54 UTC |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 184,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003233 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,062 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:52 UTC |
Grow BrianChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 189,369 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003228 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,369 Underlying: Class A Common Stock · 189,369 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:52 UTC |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 183,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003228 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,490 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:49 UTC |
Francisco DavidChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 170,841 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003224 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,841 Underlying: Class A Common Stock · 170,841 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:49 UTC |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 165,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003224 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,095 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:43 UTC |
Korfin Michele IleneDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003214 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,245 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:48 UTC |
Quintero GilbertoDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003222 · form4.xml · nonDerivative · entry 1 Quintero Gilberto · CIK 0001927023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,245 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:42 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 732,596 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003212 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,596 Underlying: Class A Common Stock · 732,596 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:42 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 708,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003212 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,515,323 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:38 UTC |
Duraibabu PrathyushaDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003207 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,219 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 19:20 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 719 | $3.70 | $2,660.30 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,187 Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 19:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 646 | $3.70 | $2,390.20 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,148 Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:19 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 6,123 | $3.70 | $22,655.10 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,807,108 Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 656 | $3.70 | $2,427.20 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,423 Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:18 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 790 | $3.70 | $2,923.00 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,926 Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:17 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 804 | $3.70 | $2,974.80 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,939 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 6,008 | $3.70 | $22,229.60 |
DisclosureSEC source: 0001062993-25-002940 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,758 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 5,000 | $3.70 | $18,500.00 |
DisclosureSEC source: 0001062993-25-002940 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,766 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 1,252 | $3.70 | $4,632.40 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,906 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 8,657 | $3.70 | $32,030.90 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,158 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 3,453 | $3.70 | $12,776.10 |
DisclosureSEC source: 0001062993-25-002939 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,815 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 3,070 | $3.70 | $11,359.00 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,794 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 22,178 | $3.70 | $82,058.60 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,864 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 11,230 | $3.70 | $41,551.00 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,042 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 33,869 | $3.70 | $125,315.30 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,813,231 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 109,280 | $3.70 | $404,336.00 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,847,100 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 82,814 | $3.70 | $306,411.80 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,956,380 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 2,748 | $3.70 | $10,167.60 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,079 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 19,423 | $3.70 | $71,865.10 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,827 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 10,559 | $3.70 | $39,068.30 |
DisclosureSEC source: 0001062993-25-002936 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,250 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 3,883 | $3.70 | $14,367.10 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,716 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 25,739 | $3.70 | $95,234.30 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,599 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:18 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 13,744 | $3.70 | $50,852.80 |
DisclosureSEC source: 0001062993-25-002934 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 795,338 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 2,960 | $3.70 | $10,952.00 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,743 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 19,528 | $3.70 | $72,253.60 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,703 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 11,765 | $3.70 | $43,530.50 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,231 Read SEC document |
| January 10, 2025 Filed Apr 25, 2026 01:29 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 958 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0002064832-26-000183 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 958 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 10, 2025 Filed Apr 25, 2026 01:29 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionClass A Common Stock | 958 | $1.24 | $1,187.92 |
DisclosureSEC source: 0002064832-26-000183 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000727 · form4.xml · nonDerivative · entry 3 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000727 · form4.xml · nonDerivative · entry 2 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000727 · form4.xml · nonDerivative · entry 1 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.